RedHill Biopharma Ltd (NASDAQ:RDHL) announced in vivo results from a new preclinical study evaluating the effects of opaganib] on radiation-induced hematologic…
Editas Medicine Inc (NASDAQ:EDIT) announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine. EDIT-101…
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.
Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat,
Evaxion Biotech A/S (NASDAQ:EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer…
Cannabis and psychedelics-focused Pharma company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1 2023.
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) announced on Thursday that it has signed a deal for the provision of software services with an Israeli air conditioning company.
- The PhALLCON Study Is the First Global, Phase 3, Registrational, and Only Head-To-Head Clinical Trial Comparing Two TKIs in Frontline Ph+ ALL
- Primary Endpoint Result Shows Superiority Compared to Imatinib as